In this weeks video, Dr. Brian G.M. Durie explains how the ARROW study demonstrated efficacy and low toxicity for weekly…
Browsing: Multiple Myeloma
In this video, Dr. Brian G.M. Durie explains how high-dose melphalan therapy that precedes an ASCT may cause some side…
In this video, Dr. Brian G.M. Durie explains which lifestyle choices can improve myeloma patients outcomes. BOTTOM LINE: Live as…
In this video, Dr. Brian G.M. Durie explains why MRD-negative status and MRD-positive status are not clear indicators for next…
In this weeks video, Dr. Brian G.M. Durie recommends ways myeloma patients can avoid infections, such as using preventative antibiotics,…
In this weeks video, Dr. Brian G.M. Durie discusses the ways patients can learn from one another at IMF-affiliated support…
Drug development for multiple myeloma (MM) has recently reached such heights that there is now a plethora of novel inhibitors…
In this weeks video, Dr. Brian G.M. Durie provides helpful hints for myeloma patients to follow healthful diets. The BOTTOM…
In this weeks video, Dr. Brian G.M. Durie explains why a Freelite test may be inaccurate. BOTTOM LINE: Discuss abnormal…
The use of checkpoint inhibitors in multiple myeloma (MM) is an exciting area. The data from two KEYNOTE studies examining…
Vincent Rajkumar, MD, of the Mayo Clinic, Rochester, MN, gives an overview of his top 5 abstract presentations at the…
Multiple myeloma (MM) updates in the relapsed/refractory setting at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago,…
CAR T-cells are an exciting therapeutic avenue for multiple myeloma (MM). Here, Noopur Raje, MD, of Massachusetts General Hospital Cancer…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Stephan Grupp, MD, PhD, of…
A number of novel treatment strategies for multiple myeloma (MM) are being studied. A few such studies are discussed here…
Multiple myeloma (MM) is an expensive cancer to treat, with costly drugs that are often used in combination. In this…
The anti-BCMA CAR T-cell therapy bb2121 looks extremely promising in multiple myeloma (MM). Here, Noopur Raje, MD, of Massachusetts General…
IV administration of daratumumab has several issues, including a long infusion time (~7 h) and the likelihood of infusion-related toxicities.…
Ajai Chari, MD, PhD, of Mount Sinai School of Medicine, New York, NY, presented data from the recent Phase Ib…
Francesca Gay, MD, of the University of Torino, Torino, Italy, provides an efficacy data update from the FORTE trial (NCT02203643),…
While there are many clinical trials exploring the effect of various novel agents in combination with lenalidomide-dexamethasone therapy in multiple…
Prof Wee Joo Chng, MD discusses the importance of Minimal Residual Disease (MRD) testing in Multiple Myeloma
Kinase inhibitors are one of the most successful forms of therapy for hematological malignancies, with further potential due to new…
The contemporary viewpoint is that multiple myeloma (MM) is a group of separate diseases, rather than just one type of…
Monika Engelhardt, MD, of the University Medical Center Freiburg, Freiburg, Germany, discusses a promising study conducted at her center using…
In this video, Fabio Malavasi, MD, of the University of Turin, Turin, Italy, discusses immunotherapy in multiple myeloma (MM) from…
Despite recent advances in drug development, autologous stem cell transplant (ASCT) is still, to date, the most effective treatment for…
Abstracts are often the most informative parts of scientific publications, as they contain a complete overview of the entire paper.…
While daratumumab is one of the most effective treatments for multiple myeloma (MM), ~50% of all patients who the drug…
Autologous stem cell transplantation (ASCT) for multiple myeloma (MM) patients has often been capped at 65 years of age. However,…
Autologous stem cell transplantation is here to stay for multiple myeloma (MM). However, once a treatment has been developed, there…
Measurable residual disease (MRD) status is a valuable prognostic marker in multiple myeloma (MM), but questions still remain. Speaking from…
Measurable residual disease (MRD) is evaluated and analyzed in clinical trials, but less attention is currently given to it in…
Elderly patients with multiple myeloma (MM) are often denied intensive treatment due to the fear they will not be able…
Measurable residual disease (MRD) can be determined using a variety of techniques. However, the majority of trials perform bone marrow…
While it is understandable that elderly patients with multiple myeloma (MM) are generally excluded from more aggressive treatments, Mohamad Mohty,…
Noa Biran, MD, discusses her thoughts on the promising combination of carfilzomib and daratumumab in revlimid-refractory multiple myeloma patients at…
Noa Biran, MD, talks about her thoughts on the promising combination of carfilzomib and daratumumab in revlimid-refractory multiple myeloma patients…
Noa Biran, MD, talks about her thoughts on the logistics involved in delivering CAR-T in the BB2121 study in multiple…
There are many questions surrounding minimal residual disease (MRD) detection and its role in decision making; for example, whether drug…
Ola Landgren, MD, PhD, from Memorial Sloan Kettering Cancer Center, NY, describes novel uses for minimal residual disease (MRD) measurement…
Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, discusses an exciting preclinical investigation of the…
Treatments for multiple myeloma (MM) in newly diagnosed and relapsed patients differ between regions, particularly with the rapid advancements in…
Previous clinical trial investigations have established that daratumumab plus bortezomib, melphalan and prednisone, also known as dara+VMP, is significantly more…
The 23rd congress of the European Haematology Association (EHA) 2018, held in Stockholm, Sweden, presented exciting data from multiple myeloma…
A small proportion (~20%) of multiple myeloma (MM) patients are at a high risk of relapse and aggressive disease progression.…
Daratumumab is one of the most promising new therapies in multiple myeloma (MM). Here, Matthew Jenner, MBBS, MRCP, FRCPath, PhD,…
Lenalidomide monotherapy has proven to be an effective maintenance treatment for multiple myeloma (MM). Matthew Jenner, MBBS, MRCP, FRCPath, PhD,…
Noa Biran, MD, discusses the impact of the BB2121 study in multiple myeloma patients and how the results compare to…
The 23rd Congress of the European Hematological Association (EHA) 2018 in Stockholm, Sweden, saw many researchers presenting the newest data…